Biogen Idec and Swedish Orphan Biovitrum Update Hemophilia Partnership Agreement

22-Feb-2010 - USA

Biogen Idec and Swedish Orphan Biovitrum announced that they have restructured the collaboration agreement for the companies' long-acting, recombinant Factor VIII Fc fusion protein (rFVIIIFc) in hemophilia A patients and the recombinant factor IX Fc fusion protein (rFIXFc) in hemophilia B patients.

Under the amended agreement, Biogen Idec will assume full development responsibilities and costs, as well as manufacturing rights for the rFVIIIFc and rFIXFc programs. Biogen Idec also gains marketing responsibility for the rest-of-world territories that had previously been shared between the two companies, in addition to its existing commercial rights in North America. Swedish Orphan Biovitrum will retain commercial rights in Europe, Russia, Turkey and the Middle East. The cross-royalty rate has been reduced for both companies. The royalty rates will be further adjusted until Biogen Idec's increased costs are reimbursed.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances